Sales & Marketing News | pharmaphorum

News

Bottle of Tavneos with two pills in front of it

EMA looks into 'data integrity' issue with Amgen's Tavneos

Concerns about efficacy data in the main trial behind the approvals of Amgen and CSL Vifor's Tavneos have triggered a review in the EU.

News

FDA starts review of Summit's VEGFxPD-1 bispecific

Summit moves ahead in the race to bring a VEGFxPD-(L)1 drug to market, after the FDA started a review of ivonescimab in lung cancer.

News

Tenpoint eyes presbyopia drug launch after FDA nod

Tenpoint is set to join the US market for drugs to treat presbyopia, taking on rival therapies from AbbVie, Orasis, and LENZ with a dual-acting rival.

News

Digital musculoskeletal care firm Sword buys rival Kaia

US digital physical therapy specialist Sword Health has bought its competitor Kaia Health for $285 million, positioning it for expansion in Europe.

News

ADHD in wooden letters surrounded by white pills

Otsuka preps for July decision on centanafadine for ADHD

The FDA has started a priority review of Otsuka's triple-acting drug for ADHD, setting up a decision on the first-in-class drug in July.

News

Halozyme diversifies in drug delivery with Surf Bio buy

Halozyme has expanded its portfolio of drug delivery technologies for a second time in a few months with the acquisition of Surf Bio for up to $400m.

EMA looks into 'data integrity' issue with Amgen's Tavneos

FDA starts review of Summit's VEGFxPD-1 bispecific

Tenpoint eyes presbyopia drug launch after FDA nod

Digital musculoskeletal care firm Sword buys rival Kaia

Otsuka preps for July decision on centanafadine for ADHD

Halozyme diversifies in drug delivery with Surf Bio buy

AI specialist Chai Discovery raises $400m

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks